Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

ACAT1作为治疗靶标及其与阿尔茨海默氏病的遗传关系

卷 16, 期 8, 2019

页: [699 - 709] 页: 11

弟呕挨: 10.2174/1567205016666190823125245

价格: $65

摘要

背景：阿尔茨海默氏病（AD）是一种慢性和进行性疾病，会在物理，心理和经济方面影响护理人员，家庭和社会。当前可用的药物只能改善认知症状，对进展无影响且不能治愈，因此识别和研究新的药物靶标很重要。有证据表明胆固醇稳态紊乱可能与AD病理有关，尤其是细胞内胆固醇和由酰基辅酶A形成的细胞质胆固醇酯的区室化：胆固醇酰基转移酶1（ACAT1）可能参与了β-淀粉样蛋白（Aβ）的调节肽，参与AD。阻断ACAT1活性可获得有益的效果，因此，有人提出ACAT1可以成为潜在的新治疗靶标。本综述讨论了胆固醇稳态在AD病理中的作用，尤其是在使用ACAT抑制剂的情况下，以及它们如何作为一种治疗方法被提出。此外，还讨论了ACAT和AD的遗传关系。 结论：尽管有来自细胞和动物研究的多条证据表明，抑制ACAT是降低脑Aβ的有效方法，但在进入下一阶段之前，在机制和关注方面仍存在信息空白。另外，药物遗传学可能对理解AD以随后提出新的治疗方法有用。但是，在该区域中仍然有很多缺少的信息。

关键词: 阿尔茨海默氏病，胆固醇代谢，胆固醇酯，抑制ACAT1，药物遗传学，治疗靶标。

« Previous Next »
[1]
Organización Mundial de la Salud y Alzheimer’s Disease International. Demencia: una prioridad en salud pública [monograph on the internet Washington: Organización Panamericana de la Salud; 2013 [cited 2019 jan 20 Available from: https://www.who.int/mental_health/publications/dementia_report_2012/es/
[2]
Di Paolo G, Kim TW. Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci 12(5): 284-96. 2011
[http://dx.doi.org/10.1038/nrn3012] [PMID: 21448224]
[3]
Cubinkova V, Valachova B, Uhrinova I, Brezovakova V, Smolek T, Jadhav S, et al. Alternative hypotheses related to Alzheimer’s disease. Bratisl Lek Listy 119(4): 210-6. 2018
[PMID: 29663818]
[4]
Arenas F, Garcia-Ruiz C, Fernandez-Checa JC. Intracellular cholesterol trafficking and impact in neurodegeneration. Front Mol Neurosci 10: 382. 2017
[http://dx.doi.org/10.3389/fnmol.2017.00382] [PMID: 29204109]
[5]
Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer’s disease β -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98(10): 5856-61. 2001
[http://dx.doi.org/10.1073/pnas.081620098] [PMID: 11296263]
[6]
Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4): 321-31. 2000
[http://dx.doi.org/10.1006/nbdi.2000.0304] [PMID: 10964604]
[7]
Kivipelto M, Helkala EL, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 56(12): 1683-9. 2001
[http://dx.doi.org/10.1212/WNL.56.12.1683] [PMID: 11425934]
[8]
Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61(2): 199-205. 2003
[http://dx.doi.org/10.1212/01.WNL.0000070182.02537.84] [PMID: 12874399]
[9]
Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64(2): 277-81. 2005
[http://dx.doi.org/10.1212/01.WNL.0000149519.47454.F2] [PMID: 15668425]
[10]
Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat Cell Biol 3(10): 905-12. 2001
[http://dx.doi.org/10.1038/ncb1001-905] [PMID: 11584272]
[11]
Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44(2): 227-38. 2004
[http://dx.doi.org/10.1016/j.neuron.2004.08.043] [PMID: 15473963]
[12]
Huttunen HJ, Greco C, Kovacs DM. Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett 581(8): 1688-92. 2007
[http://dx.doi.org/10.1016/j.febslet.2007.03.056] [PMID: 17412327]
[13]
Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, et al. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J 23(11): 3819-28. 2009
[http://dx.doi.org/10.1096/fj.09-134999] [PMID: 19625658]
[14]
Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci USA 107(7): 3081-6. 2010
[http://dx.doi.org/10.1073/pnas.0913828107] [PMID: 20133765]
[15]
Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, et al. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J Neuropathol Exp Neurol 69(8): 777-88. 2010
[http://dx.doi.org/10.1097/NEN.0b013e3181e77ed9] [PMID: 20613640]
[16]
Murphy SR, Chang CC, Dogbevia G, Bryleva EY, Bowen Z, Hasan MT, et al. Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer’s disease. Mol Ther 21(8): 1497-506. 2013
[http://dx.doi.org/10.1038/mt.2013.118] [PMID: 23774792]
[17]
Shibuya Y, Chang CC, Huang L-H, Bryleva EY, Chang TY. Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance. J Neurosci 34(43): 14484-501. 2014
[http://dx.doi.org/10.1523/JNEUROSCI.2567-14.2014] [PMID: 25339759]
[18]
Shibuya Y, Niu Z, Bryleva EY. Harris BT2, Murphy SR1, Kheirollah A, et al.Acyl-coenzyme A: cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol Aging 36(7): 2248-59. 2015
[http://dx.doi.org/10.1016/j.neurobiolaging.2015.04.002] [PMID: 25930235]
[19]
Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LM, Lütjohann D, Thal D, et al. Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer’s disease. Mol Psychiatry 8(6): 635-8. 2003
[http://dx.doi.org/10.1038/sj.mp.4001296] [PMID: 12851640]
[20]
Zhao FG, Wang YH, Yang JF, Ma QL, Tang Z, Dong XM, et al. Association between acyl-coenzyme A: cholesterol acyltransferase gene and risk for Alzheimer’s disease in Chinese. Neurosci Lett 388(1): 17-20. 2005
[http://dx.doi.org/10.1016/j.neulet.2005.06.020] [PMID: 16043284]
[21]
Bertram L, Hsiao M, Mullin K, Parkinson M, Menon R, Moscarillo TJ, et al. ACAT1 is not associated with Alzheimer’s disease in two independent family-based samples. Mol Psychiatry 10(6): 522-4. 2005
[http://dx.doi.org/10.1038/sj.mp.4001646] [PMID: 15768051]
[22]
Lämsä R, Helisalmi S, Herukka S-K, Tapiola T, Pirttila T, Vepsalainen S, et al. Study on the association between SOAT1 polymorphisms, Alzheimer’s disease risk and the level of CSF biomarkers. Dement Geriatr Cogn Disord 24(2): 146-50. 2007
[http://dx.doi.org/10.1159/000105164] [PMID: 17622762]
[23]
Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 12(2): 105-12. 2001
[http://dx.doi.org/10.1097/00041433-200104000-00003] [PMID: 11264981]
[24]
Petrov AM, Kasimov MR, Zefirov AL. Brain cholesterol metabolism and its defects: Linkage to neurodegenerative diseases and synaptic dysfunction. Acta Naturae 8(1): 58-73. 2016
[http://dx.doi.org/10.32607/20758251-2016-8-1-58-73] [PMID: 27099785]
[25]
Canevari L, Clark JB. Alzheimer’s disease and cholesterol: the fat connection. Neurochem Res 32(4-5): 739-50. 2007
[http://dx.doi.org/10.1007/s11064-006-9200-1] [PMID: 17191138]
[26]
Björkhem I, Meaney S, Fogelman AM. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24(5): 806-15. 2004
[http://dx.doi.org/10.1161/01.ATV.0000120374.59826.1b] [PMID: 14764421]
[27]
Martín MG, Pfrieger F, Dotti CG. Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep 15(10): 1036-52. 2014
[http://dx.doi.org/10.15252/embr.201439225] [PMID: 25223281]
[28]
Moutinho M, Nunes MJ, Rodrigues E. Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond. Biochim Biophys Acta 1861(12 Pt A): 1911-20. 2016
[http://dx.doi.org/10.1016/j.bbalip.2016.09.011] [PMID: 27663182]
[29]
Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, et al. On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314(1-2): 45-8. 2001
[http://dx.doi.org/10.1016/S0304-3940(01)02277-7] [PMID: 11698143]
[30]
Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278(25): 22980-8. 2003
[http://dx.doi.org/10.1074/jbc.M303415200] [PMID: 12686551]
[31]
Chang CC, Chen J, Thomas MA, Cheng D, Del Priore VA, Newton RS, et al. Regulation and immunolocalization of acyl-coenzyme A: cholesterol acyltransferase in mammalian cells as studied with specific antibodies. J Biol Chem 270(49): 29532-40. 1995
[http://dx.doi.org/10.1074/jbc.270.49.29532] [PMID: 7493995]
[32]
Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287(4): 2678-88. 2012
[http://dx.doi.org/10.1074/jbc.M111.274142] [PMID: 22134919]
[33]
Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res 44(9): 1780-9. 2003
[http://dx.doi.org/10.1194/jlr.M300164-JLR200] [PMID: 12810827]
[34]
Lütjohann D, Meichsner S, Pettersson H. Lipids in Alzheimer’s disease and their potential for therapy. Clin Lipidol 7: 65-78. 2012
[http://dx.doi.org/10.2217/clp.11.74]
[35]
Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 390(4): 287-93. 2009
[http://dx.doi.org/10.1515/BC.2009.035] [PMID: 19166320]
[36]
Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3(77): 77sr1. 2011
[http://dx.doi.org/10.1126/scitranslmed.3002369] [PMID: 21471435]
[37]
Solomon A, Kivipelto M. Cholesterol-modifying strategies for Alzheimer’s disease. Expert Rev Neurother 9(5): 695-709. 2009
[http://dx.doi.org/10.1586/ern.09.25] [PMID: 19402779]
[38]
Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurol Zentralblatt 23: 1129-36. 1906
[39]
St Clair D, Rennie M, Slorach E, Norrman J, Yates C, Carothers A. Apolipoprotein E ε 4 allele is a risk factor for familial and sporadic presenile Alzheimer’s disease in both homozygote and heterozygote carriers. J Med Genet 32(8): 642-4. 1995
[http://dx.doi.org/10.1136/jmg.32.8.642] [PMID: 7473659]
[40]
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123): 921-3. 1993
[http://dx.doi.org/10.1126/science.8346443] [PMID: 8346443]
[41]
Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43(8): 1467-72. 1993
[http://dx.doi.org/10.1212/WNL.43.8.1467] [PMID: 8350998]
[42]
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90(5): 1977-81. 1993
[http://dx.doi.org/10.1073/pnas.90.5.1977] [PMID: 8446617]
[43]
Shibuya Y, Chang CC, Chang T-Y. ACAT1/SOAT1 as a therapeutic target for Alzheimer’s disease. Future Med Chem 7(18): 2451-67. 2015
[http://dx.doi.org/10.4155/fmc.15.161] [PMID: 26669800]
[44]
Eckert GP, Wood WG, Müller WE. Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes. J Neural Transm (Vienna) 108(8-9): 1051-64. 2001
[http://dx.doi.org/10.1007/s007020170024] [PMID: 11716141]
[45]
Lütjohann D, von Bergmann K. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 36(Suppl. 2): S102-6. 2003
[http://dx.doi.org/10.1055/s-2003-43053] [PMID: 14574622]
[46]
Wood WG, Li L, Müller WE, Eckert GP. Cholesterol as a causative factor in Alzheimer’s disease: a debatable hypothesis. J Neurochem 129(4): 559-72. 2014
[http://dx.doi.org/10.1111/jnc.12637] [PMID: 24329875]
[47]
Posse de Chaves E. Reciprocal regulation of cholesterol and beta amyloid at the subcellular level in Alzheimer’s disease. Can J Physiol Pharmacol 90(6): 753-64. 2012
[http://dx.doi.org/10.1139/y2012-076] [PMID: 22626060]
[48]
Maulik M, Westaway D, Jhamandas JH, Kar S. Role of cholesterol in APP metabolism and its significance in Alzheimer’s disease pathogenesis. Mol Neurobiol 47(1): 37-63. 2013
[http://dx.doi.org/10.1007/s12035-012-8337-y] [PMID: 22983915]
[49]
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256(5054): 184-5. 1992
[http://dx.doi.org/10.1126/science.1566067] [PMID: 1566067]
[50]
Walker LC, Lynn DG, Chernoff YO. A standard model of Alzheimer’s disease? Prion 12(5-6): 261-5. 2018
[http://dx.doi.org/10.1080/19336896.2018.1525256] [PMID: 30220236]
[51]
Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol Rev 54(3): 469-525. 2002
[http://dx.doi.org/10.1124/pr.54.3.469] [PMID: 12223532]
[52]
Araki W, Tamaoka A. Amyloid beta-protein and lipid rafts: focused on biogenesis and catabolism. Front Biosci 20: 314-24. 2015
[http://dx.doi.org/10.2741/4311] [PMID: 25553453]
[53]
Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 23(1): 111-22. 2006
[http://dx.doi.org/10.1080/09687860500496417] [PMID: 16611586]
[54]
Saxena U. Lipid metabolism and Alzheimer’s disease: pathways and possibilities. Expert Opin Ther Targets 13(3): 331-8. 2009
[http://dx.doi.org/10.1517/14728220902738720] [PMID: 19236155]
[55]
Khan A, Corbett A, Ballard C. Emerging amyloid and tau targeting treatments for Alzheimer’s disease. Expert Rev Neurother 17(7): 697-711. 2017
[http://dx.doi.org/10.1080/14737175.2017.1326819] [PMID: 28490214]
[56]
Kim Y, Kim C, Jang HY, Mook-Jung I. Inhibition of cholesterol biosynthesis reduces γ -secretase activity and amyloid-β generation. J Alzheimers Dis 51(4): 1057-68. 2016
[http://dx.doi.org/10.3233/JAD-150982] [PMID: 26923021]
[57]
Vetrivel KS, Thinakaran G. Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments. Neurology 66(2)(Suppl. 1): S69-73. 2006
[http://dx.doi.org/10.1212/01.wnl.0000192107.17175.39] [PMID: 16432149]
[58]
Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bièche I, et al. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer’s disease. Brain 138(Pt 8): 2383-98. 2015
[http://dx.doi.org/10.1093/brain/awv166] [PMID: 26141492]
[59]
Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J, et al. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim Biophys Acta 1801(8): 846-52. 2010
[http://dx.doi.org/10.1016/j.bbalip.2010.05.010] [PMID: 20580937]
[60]
Daneschvar HL, Aronson MD, Smetana GW. Do statins prevent Alzheimer’s disease? A narrative review. Eur J Intern Med 26(9): 666-9. 2015
[http://dx.doi.org/10.1016/j.ejim.2015.08.012] [PMID: 26342722]
[61]
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356(9242): 1627-31. 2000
[PMID: 11089820]
[62]
Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59(2): 223-7. 2002
[http://dx.doi.org/10.1001/archneur.59.2.223] [PMID: 11843693]
[63]
Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57(10): 1439-43. 2000
[http://dx.doi.org/10.1001/archneur.57.10.1439] [PMID: 11030795]
[64]
Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 88(11): 1213-21. 2013
[http://dx.doi.org/10.1016/j.mayocp.2013.07.013] [PMID: 24095248]
[65]
Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71(5): 344-50. 2008
[http://dx.doi.org/10.1212/01.wnl.0000319647.15752.7b] [PMID: 18663180]
[66]
Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 5(4): 416-21. 2008
[http://dx.doi.org/10.2174/156720508785132316] [PMID: 18690839]
[67]
Haag MDM, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80(1): 13-7. 2009
[http://dx.doi.org/10.1136/jnnp.2008.150433] [PMID: 18931004]
[68]
Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008; 70(19 Pt 2): 1795-802.
[http://dx.doi.org/10.1212/01.wnl.0000288181.00826.63] [PMID: 18199831]
[69]
McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev (1): CD003160 2016
[PMID: 26727124]
[70]
Bhattacharyya R, Kovacs DM. ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801(8): 960-5. 2010
[http://dx.doi.org/10.1016/j.bbalip.2010.04.003] [PMID: 20398792]
[71]
Li J, Gu D, Lee SSY, Song B, Bandyopadhyay S, Chen S, et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene 35(50): 6378-88. 2016
[http://dx.doi.org/10.1038/onc.2016.168] [PMID: 27132508]
[72]
Bemlih S, Poirier MD, El Andaloussi A. Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines. Cancer Biol Ther 9(12): 1025-32. 2010
[http://dx.doi.org/10.4161/cbt.9.12.11875] [PMID: 20404512]
[73]
Lee SS, Li J, Tai JN, Ratliff TL, Park K, Cheng JX. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. ACS Nano 9(3): 2420-32. 2015
[http://dx.doi.org/10.1021/nn504025a] [PMID: 25662106]
[74]
Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat 122(3): 661-70. 2010
[http://dx.doi.org/10.1007/s10549-009-0594-8] [PMID: 19851860]
[75]
Rogers MA, Liu J, Song BL, Li BL, Chang CC, Chang TY. Acyl-CoA:cholesterol acyltransferases (ACATs/SOATs): Enzymes with multiple sterols as substrates and as activators. J Steroid Biochem Mol Biol 151: 102-7. 2015
[http://dx.doi.org/10.1016/j.jsbmb.2014.09.008] [PMID: 25218443]
[76]
Chang CC, Huh HY, Cadigan KM, Chang TY. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem 268(28): 20747-55. 1993
[PMID: 8407899]
[77]
Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T, et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease. Lipids Health Dis 12: 68. 2013
[http://dx.doi.org/10.1186/1476-511X-12-68] [PMID: 23659495]
[78]
Roth BD. ACAT inhibitors: evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents. Drug Discov Today 3: 19-25. 1998
[http://dx.doi.org/10.1016/S1359-6446(97)01123-9]
[79]
Hainer JW, Terry JG, Connell JM, Zyruk H, Jenkins RM, Shand DL, et al. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther 56(1): 65-74. 1994
[http://dx.doi.org/10.1038/clpt.1994.102] [PMID: 8033496]
[80]
Llaverias G, Alegret M. Inhibidores de la acil coenzima A:colesterol aciltransferasa (ACAT): mecanismos y perspectivas terapéuticas. Clin Invest Arter 16: 250-61. 2004
[http://dx.doi.org/10.1016/S0214-9168(04)79002-6]
[81]
Bocan TM, Mueller SB, Uhlendorf PD, Newton RS, Krause BR. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. Arterioscler Thromb 11(6): 1830-43. 1991
[http://dx.doi.org/10.1161/01.ATV.11.6.1830] [PMID: 1931885]
[82]
Lee HT, Sliskovic DR, Picard JA, Roth BD, Wierenga W, Hicks JL, et al. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J Med Chem 39(26): 5031-4. 1996
[http://dx.doi.org/10.1021/jm960674d] [PMID: 8978833]
[83]
Tardif JC, Grégoire J, L’Allier PL, et al. Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004; 110(21): 3372-7.
[http://dx.doi.org/10.1161/01.CIR.0000147777.12010.EF] [PMID: 15533865]
[84]
Nicholls SJ, Sipahi I, Schoenhagen P, Wisniewski L, Churchill T, Crowe T, et al. ACTIVATE Investigators.Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. Am Heart J 152(1): 67-74. 2006
[http://dx.doi.org/10.1016/j.ahj.2005.10.025] [PMID: 16824833]
[85]
Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, et al. CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 301(11): 1131-9. 2009
[http://dx.doi.org/10.1001/jama.301.11.1131] [PMID: 19293413]
[86]
Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, et al. ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators.Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354(12): 1253-63. 2006
[http://dx.doi.org/10.1056/NEJMoa054699] [PMID: 16554527]
[87]
Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci 28(33): 8354-60. 2008
[http://dx.doi.org/10.1523/JNEUROSCI.0616-08.2008] [PMID: 18701698]
[88]
Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78(4): 631-43. 2013
[http://dx.doi.org/10.1016/j.neuron.2013.04.014] [PMID: 23623698]
[89]
Mizushima N. Autophagy: process and function. Genes Dev 21(22): 2861-73. 2007
[http://dx.doi.org/10.1101/gad.1599207] [PMID: 18006683]
[90]
Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-β, and Tau: effects on cognitive impairments. J Biol Chem 285(17): 13107-20. 2010
[http://dx.doi.org/10.1074/jbc.M110.100420] [PMID: 20178983]
[91]
Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. Science 332(6036): 1429-33. 2011
[http://dx.doi.org/10.1126/science.1204592] [PMID: 21617040]
[92]
Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, Madra M, et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J 31(21): 4106-23. 2012
[http://dx.doi.org/10.1038/emboj.2012.202] [PMID: 22892566]
[93]
Chen Y, Zhu L, Ji L, Yang Y, Lu L, Wang X, et al. Silencing the ACAT1 Gene in Human SH-SY5Y Neuroblastoma Cells Inhibits the Expression of Cyclo-Oxygenase 2 (COX2) and Reduces β-Amyloid-Induced Toxicity Due to Activation of Protein Kinase C (PKC) and ERK. Med Sci Monit 24: 9007-18. 2018
[http://dx.doi.org/10.12659/MSM.912862] [PMID: 30541014]
[94]
Karch CM, Cruchaga C, Goate AM. Alzheimer’s disease genetics: from the bench to the clinic. Neuron 83(1): 11-26. 2014
[http://dx.doi.org/10.1016/j.neuron.2014.05.041] [PMID: 24991952]
[95]
Cacabelos R, Cacabelos P, Torrellas C, Tellado I, Carril JC. Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development. New York 2014; 323-556.
[96]
Cacabelos R, Torrellas C, Teijido O, Carril JC. Pharmacogenetic considerations in the treatment of Alzheimer’s disease. Pharmacogenomics 17(9): 1041-74. 2016
[http://dx.doi.org/10.2217/pgs-2016-0031] [PMID: 27291247]
[97]
Bai F, Yuan Y, Shi Y, Zhang Z. Multiple genetic imaging study of the association between cholesterol metabolism and brain functional alterations in individuals with risk factors for Alzheimer’s disease. Oncotarget 7(13): 15315-28. 2016
[http://dx.doi.org/10.18632/oncotarget.8100] [PMID: 26985771]
[98]
Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease. Expert Opin Pharmacother 6(12): 1967-87. 2005
[http://dx.doi.org/10.1517/14656566.6.12.1967] [PMID: 16197352]
[99]
Liu X, Yue C, Xu Z, Shu H, Pu M, Yu H, et al. Association study of candidate gene polymorphisms with amnestic mild cognitive impairment in a Chinese population. PLoS One 7(7)e41198 2012
[http://dx.doi.org/10.1371/journal.pone.0041198] [PMID: 22911757]
[100]
Picard C, Julien C, Frappier J, Miron J, Théroux L, Dea D, et al. United Kingdom Brain Expression Consortium and for the Alzheimer’s Disease Neuroimaging Initiative. Alterations in cholesterol metabolism-related genes in sporadic Alzheimer’s disease. Neurobiol Aging 66: 180.e1-9. 2018
[http://dx.doi.org/10.1016/j.neurobiolaging.2018.01.018] [PMID: 29503034]
[101]
Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 5(11)e13950 2010
[http://dx.doi.org/10.1371/journal.pone.0013950] [PMID: 21085570]
[102]
Liu Q, An Y, Ma W, Feng L, Wang C, Lu Y, et al. Highcholesterol diet results in elevated amyloidβ and oxysterols in rats. Mol Med Rep 17(1): 1235-40. 2018
[PMID: 29115521]

Rights & Permissions Print Cite
Article Metrics
50
5
© 2024 Bentham Science Publishers | Privacy Policy